ATE247486T1 - Pharmazeutische zusammensetzungen, enthaltend diclofenac und 2-hydroxypropyl-beta-cyclodextrin - Google Patents

Pharmazeutische zusammensetzungen, enthaltend diclofenac und 2-hydroxypropyl-beta-cyclodextrin

Info

Publication number
ATE247486T1
ATE247486T1 AT94308690T AT94308690T ATE247486T1 AT E247486 T1 ATE247486 T1 AT E247486T1 AT 94308690 T AT94308690 T AT 94308690T AT 94308690 T AT94308690 T AT 94308690T AT E247486 T1 ATE247486 T1 AT E247486T1
Authority
AT
Austria
Prior art keywords
cyclodextrin
hydroxypropyl
beta
diclofenac
pharmaceutical compositions
Prior art date
Application number
AT94308690T
Other languages
English (en)
Inventor
Mark David Bodley
Lawrence John Penkler
Lueta Ann Glintenkamp
Oudtshoorn Michiel Coenraa Van
Original Assignee
Farmarc Nederland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66648427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE247486(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmarc Nederland Bv filed Critical Farmarc Nederland Bv
Application granted granted Critical
Publication of ATE247486T1 publication Critical patent/ATE247486T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94308690T 1993-12-02 1994-11-24 Pharmazeutische zusammensetzungen, enthaltend diclofenac und 2-hydroxypropyl-beta-cyclodextrin ATE247486T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA939031 1993-12-02

Publications (1)

Publication Number Publication Date
ATE247486T1 true ATE247486T1 (de) 2003-09-15

Family

ID=66648427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94308690T ATE247486T1 (de) 1993-12-02 1994-11-24 Pharmazeutische zusammensetzungen, enthaltend diclofenac und 2-hydroxypropyl-beta-cyclodextrin

Country Status (14)

Country Link
US (1) US5679660A (de)
EP (1) EP0658347B1 (de)
JP (1) JP3877787B2 (de)
KR (1) KR100349754B1 (de)
CN (1) CN1094349C (de)
AT (1) ATE247486T1 (de)
AU (1) AU687903B2 (de)
CA (1) CA2136492C (de)
DE (1) DE69433052T2 (de)
DK (1) DK0658347T3 (de)
ES (1) ES2204909T3 (de)
IL (1) IL111755A (de)
MY (1) MY113981A (de)
ZA (1) ZA949182B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
DE19903275A1 (de) * 1999-01-28 2000-08-03 Merck Patent Gmbh Lyophilisate mit verbesserter Rekonstituierbarkeit
US8173164B2 (en) * 1999-06-17 2012-05-08 Gruenenthal Gmbh Oral administration forms for administering a fixed tramadol and diclofenac combination
US6303157B1 (en) 2000-05-31 2001-10-16 Kava Pharmaceuticals, Inc. Extracts of kava-kava
US20040029831A1 (en) * 2000-05-31 2004-02-12 Kava Pharmaceuticals, Inc. Extracts of kava-kava
KR100473716B1 (ko) * 2002-03-27 2005-03-08 주식회사 참 존 7-디하이드로콜레스테롤 및 사이클로덱스트린의 포접복합체, 이를 포함하는 화장료 조성물 및7-디하이드로콜레스테롤의 안정화방법
ES2342380T3 (es) * 2002-12-02 2010-07-06 BHARAT SERUMS & VACCINES LTD. Composiciones de ifosfamida para administracion parenteral y un procedimiento para su preparacion.
AU2011221386B2 (en) * 2004-03-10 2013-02-07 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
AU2004317520B2 (en) * 2004-03-10 2011-06-09 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
ITMI20041245A1 (it) 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
NZ554779A (en) * 2005-02-01 2011-02-25 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts
BRPI0709410A2 (pt) * 2006-03-20 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético
KR20150050595A (ko) 2006-03-28 2015-05-08 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
AU2012209035B9 (en) * 2006-03-28 2014-05-22 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
CN103932972A (zh) * 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP6320917B2 (ja) 2011-07-20 2018-05-09 ホスピーラ インコーポレイテッド 疼痛を治療する方法
US20140187635A1 (en) 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
EP3216443A1 (de) 2016-03-10 2017-09-13 Athenion AG Kapsel zur getränkevorbereitung aus einem solubilisat
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
US11110073B2 (en) 2017-03-24 2021-09-07 Cadila Healthcare Limited Storage stable aqueous injectable solution comprising diclofenac
EP3388054A1 (de) 2017-04-12 2018-10-17 Athenion AG Spenderkappe mit einem solubilisat eines pharmazeutisch wirksamen mittels oder nahrungszusatzes
SG11202005297TA (en) * 2017-12-15 2020-07-29 Univ Australian National Compounds for treating and preventing extracellular histone mediated pathologies
US11707443B2 (en) 2019-09-26 2023-07-25 Rk Pharma Inc. Storage stable aqueous parenteral solutions comprising diclofenac

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1012075B (zh) * 1986-02-19 1991-03-20 坦尼科有限公司 金属表面防锈油及其设备方法
CH673395A5 (de) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
ES2058503T5 (es) * 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
AU7453191A (en) * 1990-03-02 1991-09-18 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
DE4207922A1 (de) * 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
JPH0616547A (ja) * 1992-07-01 1994-01-25 Wakamoto Pharmaceut Co Ltd 消炎点眼剤

Also Published As

Publication number Publication date
IL111755A0 (en) 1995-06-29
US5679660A (en) 1997-10-21
CN1094349C (zh) 2002-11-20
CN1110913A (zh) 1995-11-01
JPH07252144A (ja) 1995-10-03
KR100349754B1 (ko) 2002-12-18
AU687903B2 (en) 1998-03-05
EP0658347B1 (de) 2003-08-20
EP0658347A2 (de) 1995-06-21
EP0658347A3 (de) 1995-11-29
JP3877787B2 (ja) 2007-02-07
DE69433052D1 (de) 2003-09-25
CA2136492A1 (en) 1995-06-03
CA2136492C (en) 2009-05-12
IL111755A (en) 2002-08-14
DE69433052T2 (de) 2004-07-08
ZA949182B (en) 1995-07-26
MY113981A (en) 2002-07-31
KR950016717A (ko) 1995-07-20
AU7893694A (en) 1995-06-08
ES2204909T3 (es) 2004-05-01
DK0658347T3 (da) 2003-11-17

Similar Documents

Publication Publication Date Title
DE69433052D1 (de) Pharmazeutische Zusammensetzungen, enthaltend Diclofenac und 2-Hydroxypropyl-beta-Cyclodextrin
NO944207D0 (no) Farmasöytiske og andre doseringsformer
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
PT91553A (pt) Processo de preparacao de uma composicao contendo morfina
ATE124405T1 (de) 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel.
BG92179A (bg) Метод за получаване на 7-заместена-хепт-6-еноена и -хептаноена киселина и техни производни и междинни съединения
ATE123955T1 (de) Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben.
DE69434356D1 (de) Inclusion-Komplex von Beta-Cyclodextrin mit Diclofenac
FI901328A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisen (7 ,17 )-17-hydroksi-7-metyyli-19-nor-17-pregn-5(10)-en-20-yn-3-onin valmistamiseksi kiteisenä puhtaana muotona
DE59300176D1 (de) 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
DE3863859D1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
HU9203649D0 (en) Method for producing inclusion compounds of nimesulide with cyclodextrines and pharmaceutical preparatives containing these compounds
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE59409275D1 (de) Tabletten mit Thioctsäure bestimmter Korngrösse
ATE197404T1 (de) Einen für tumore cytotoxischen faktor enthaltende pharmazeutische zusammensetzung
ES2053425T1 (es) Agentes antiviricos.
DE69637442D1 (de) Wirkstoff gegen helicobacter pylori
DE69016087D1 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
NO178325C (no) Fremgangsmåte for fremstilling av et t-PA injeksjonspreparat
DE3881484D1 (de) Optisch aktive produkte von 20,21-dinoreburnamenin-derivaten, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
ATE149354T1 (de) Pharmazeutische zusammensetzung von stabilisiertem (leu 13>-motilin-hse
DE69009705D1 (de) Verbesserung der Diurese mit Cyclodextrinen und deren Derivaten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
EEWE Authorization for restitution
UEP Publication of translation of european patent specification

Ref document number: 0658347

Country of ref document: EP